# Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg®

> **NCT06869863** · PHASE1,PHASE2 · RECRUITING · sponsor: **Lomonosov Moscow State University Medical Research and Educational Center** · enrollment: 80 (estimated)

## Conditions studied

- Azoospermia, Nonobstructive
- Teratospermia
- Oligospermia
- Men Infertility

## Interventions

- **BIOLOGICAL:** Medicinal product MediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparation of solution for injection in patients with severe spermatogenesis disorders
- **OTHER:** Clostilbegit (clomiphene) 50 mg 1 tablet x 1 p a day - 3 months, Triovit - 1 tablet x 1 p a day - 3 months, Folic acid - 1 tablet x 1 p a day - 3 months.

## Key facts

- **NCT ID:** NCT06869863
- **Lead sponsor:** Lomonosov Moscow State University Medical Research and Educational Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-26
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06869863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06869863, "Study of Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Medicinal Product MediReg®". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06869863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*